Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12-Week Treatment With ASP1941 in Combination With Metformin in Patients With Type 2Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone
Latest Information Update: 14 Jan 2020
Price :
$35 *
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms BALANCE
- Sponsors Astellas Pharma
- 01 Aug 2012 Planned number of patients changed from 315 to 630 as reported by European Clinical Trials Database.
- 04 May 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 04 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.